Skip to main content

Table 1 Demographics, clinical features and biomarkers

From: Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease

  HC (n = 48) PD (n = 46) p-values
Female 32 (66.6 %) 18 (39 %) 0.85
Male 16 (33.3 %) 28 (61 %)  
Age 63 (57–67) 64 (57–71) 0.7969
Disease years - 4 (2–8.3) -
H&Y Stage - 2 (2–2.5) N.A
UPDRS- III - 23 (15.3–27) N.A
MMSE 29 (29–30) 29 (28–30) 0.0479
t-α-syn (ng/ml) 1.6 (1.3–2.2) 1.3 (1.2–1.6) <0.0001
p-S129-α-syn (pg/ml) 222 (180.5–275) 261 (206.8–296.3) <0.001
o-α-syn (pg/ml) 57 (36–106.5) 116 (76–170) <0.0001
p-S129/t-α-syn % 13.7 (9.2–18.5) 18.6 (15.7–23.3) <0.0001
o-/t-α-syn % 3.5 (2.3–6.2) 8.9 (5.2–12.2) <0.0001
t-tau (pg/ml) 229 (162–271.5) 190 (157.8–274.3) 0.1710
p-tau (pg/ml) 41.5 (29.3–50.3) 41.1 ± 16 0.5965
Aβ42 (pg/ml) 995.5 (877.5–1153) 966.5 (794–1077) 0.6745
  1. Median, interquartile ranges and p-values of Mann-Whitney U test continuous variables, Count (percentage) for categorical ones
  2. Abbreviations: HC healthy controls, PD Parkinson’s disease, H&Y Hoehn and Yahr, UPDRS- III Unified Parkinson’s Disease Rating Scale-Part-III, MMSE mini-mental state examination, t-α-syn total α-synuclein, p-S129-α-syn phosphorylated Ser 129 α-synuclein, o-α-syn oligomeric α-synuclein, t-tau total-tau, p-tau phosphyorylated-tau, Aβ42 amyloid beta-42